Yun Ji Choi
Yonsei University · Medicine
About the Lab
Professor Yun Ji Choi's research lab specializes in clinical oncology and translational cancer research, with a focus on identifying biomarkers and optimizing treatment strategies for various malignancies. The lab investigates the impact of systemic factors—such as nutritional status (e.g., hand grip strength), vitamin D levels, and inflammatory markers (e.g., CXCR4)—on cancer outcomes and quality of life in survivors. Key research directions include evaluating targeted therapies (e.g., dovitinib, gefitinib, pemetrexed) in advanced non-small cell lung cancer and urothelial carcinoma, as well as exploring the role of immune and signaling pathways in metastatic disease. The lab integrates clinical data with molecular and physiological markers to improve personalized cancer care.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15OBJECTIVES: To assess the association between hand grip strength (HGS) and health-related quality of life (HRQoL) among Korean cancer survivors. DESIGN: Population-based cross-sectional study. SETTING: A nationally representative population survey data (face-to-face interviews and health examinations were performed in mobile examination centres). PARTICIPANTS: A total of 1037 cancer survivors (person with cancer of any type who is still living) with available data on HGS and HRQoL in the sixth a
Dovitinib showed modest antitumor activity with manageable toxicities in men with mCRPC. Especially, patients who were chemo-naïve benefitted from dovitinib.
These data suggest an inverse association between circulating 25(OH)D levels and colorectal adenoma in both Western and Asian populations.
BACKGROUND: Considering cell cycle dependent cytotoxicity, intercalation of chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) may be a treatment option in non-small cell lung cancer (NSCLC). This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-naïve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. METHODS: Eligible
Serum CXCR4 level was positively correlated with metastatic sites, liver metastasis, or higher CA 19-9 level. Also, there was a significant difference in OS according to the level of CXCR4 expression. These findings suggest that serum CXCR4 levels may be a useful surrogate marker of clinical outcome in metastatic or recurrent colorectal cancer.
BACKGROUND: Pemetrexed has shown a favourable response rate of about 30% with minimal toxicity when used as a single agent for treatment of advanced urothelial carcinoma. This phase II study evaluated the efficacy and safety of pemetrexed plus cisplatin in advanced urothelial carcinoma. METHODS: This multicentre, single-arm, open-label, phase II clinical trial enrolled patients who had advanced urothelial carcinoma, ECOG PS 0-2, and measurable disease. Pemetrexed 500 mg m(-2) with cisplatin 70 m
Wernicke's encephalopathy is caused by thiamine deficiency, and is characterized by acute mental confusion, ataxia, and ophthalmoplegia. It is also a rare neurologic complication of hematopoietic stem cell transplantation (HSCT). However, because of its rare incidence, Wernicke's encephalopathy can easily be overlooked in HSCT patients, and a few misleading steps in the early stage of the disease may result in permanent neurologic disability or even mortality. We recently encountered a case of W
PURPOSE: K-MASTER project is a Korean national precision medicine platform that screened actionable mutations by analyzing next-generation sequencing (NGS) of solid tumor patients. We compared gene analyses between NGS panel from the K-MASTER project and orthogonal methods. MATERIALS AND METHODS: Colorectal, breast, non-small cell lung, and gastric cancer patients were included. We compared NGS results from K-MASTER projects with those of non-NGS orthogonal methods (KRAS, NRAS, and BRAF mutation
A bioelectronic tongue (B-ET) mimicking insect taste systems is developed for the real-time detection and discrimination of natural and artificial sweeteners. Here, a carbon nanotube field-effect transistor (CNT-FET) was hybridized with nanovesicles including the honeybee sugar taste receptor, gustatory receptor 1 of <i>Apis mellifera</i> (AmGr1). This strategy allowed us to detect glucose, a major component of nectar, down to 100 fM in real time and identify sweet tastants from other tastants.
Adenosine metabolism through adenosine receptors plays a critical role in lung cancer biology. Although recent studies showed the potential of targeting adenosine receptors as drug targets for lung cancer treatment, conventional methods for investigating receptor activities often suffer from various drawbacks, including low sensitivity and slow analysis speed. In this study, adenosine receptor activities in nonsmall cell lung cancer (NSCLC) cells were monitored in real time with high sensitivity
OBJECTIVE: This study was performed to assess the efficacy and safety profile of combination treatment with S-1 and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. DESIGN: Eligibility criteria comprised: histologically confirmed squamous cell carcinoma of the head and neck; stage three or four disease with no evidence of distant metastasis; evaluable lesions; adequate organ function; age 20-80 years; and a performance status of two or less. Cisplatin was
Myofascial pain syndrome is very common disease but cause symptoms that are easily misdiagnosed as other conditions. The authors report a case of chest pain caused by the trigger points in the scalenus muscle. A 43 year-old man had chest pain without any history of trauma or infection. And, there were not any abnormal findings by cardiology and pulmonary evaluation. On physical examination, the scalenus muscle had the trigger points, and the chest pain was successfully treated by trigger point i
Uterine müllerian adenosarcoma with sarcomatous overgrowth (MASO), uncommon in premenopausal women, is a rare variant of uterine adenosarcomas characterized by a sarcomatous portion constituting >25% of the tumor. Uterine MASO often appears as a benign, protruding cervical polyp. However, in contrast to typical müllerian adenosarcomas (MAs), MASO is a highly aggressive tumor, frequently associated with a fatal outcome. Though very rare in premenopausal women, because of the high aggressiveness a
Research Areas
Dive deeper into Yun Ji Choi's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.